These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 22682429)

  • 1. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.
    Westover AN; Halm EA
    BMC Cardiovasc Disord; 2012 Jun; 12():41. PubMed ID: 22682429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F; Le Heuzey MF; Acquaviva E; Delorme R; Mouren MC
    Arch Pediatr; 2014 Jan; 21(1):108-12. PubMed ID: 24309201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendation for Long-term Management of Adult Attention-Deficit/Hyperactivity Disorder in Military Populations, Veterans, and Dependents: A Narrative Review.
    Baughman DJ; Watson CM; Beich JW; Herboso MNJ; Cuttie LK; Marlyne AC
    Mil Med; 2024 May; 189(5-6):e1343-e1352. PubMed ID: 37878798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
    CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J; Knecht C; Szerman N; Martinez MI
    CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.
    Olfson M; Huang C; Gerhard T; Winterstein AG; Crystal S; Allison PD; Marcus SC
    J Am Acad Child Adolesc Psychiatry; 2012 Feb; 51(2):147-56. PubMed ID: 22265361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
    Silva RR; Skimming JW; Muniz R
    Clin Pediatr (Phila); 2010 Sep; 49(9):840-51. PubMed ID: 20693523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.
    Eaton C; Yong K; Walter V; Mbizvo GK; Rhodes S; Chin RF
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD013136. PubMed ID: 35844168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN; Wilde AA
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1713-4. PubMed ID: 16924941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Attitude to questionable cadiac risks in stimulant administration].
    Fegert JM; Hebebrand J;
    Z Kinder Jugendpsychiatr Psychother; 2006 Jul; 34(4):295-7. PubMed ID: 16927572
    [No Abstract]   [Full Text] [Related]  

  • 11. Stimulants and sudden death: what is a physician to do?
    Wilens TE; Prince JB; Spencer TJ; Biederman J
    Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of stroke in prescription and other amphetamine-type stimulants use: A systematic review.
    Indave BI; Sordo L; Bravo MJ; Sarasa-Renedo A; Fernández-Balbuena S; De la Fuente L; Sonego M; Barrio G
    Drug Alcohol Rev; 2018 Jan; 37(1):56-69. PubMed ID: 28485090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulants and Pediatric Cardiovascular Risk.
    Zito JM; Burcu M
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):538-545. PubMed ID: 27258470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study.
    Winterstein AG; Gerhard T; Kubilis P; Saidi A; Linden S; Crystal S; Zito J; Shuster JJ; Olfson M
    BMJ; 2012 Jul; 345():e4627. PubMed ID: 22809800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
    Awudu GA; Besag FM
    Drug Saf; 2014 Sep; 37(9):661-76. PubMed ID: 25124483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.
    Habel LA; Cooper WO; Sox CM; Chan KA; Fireman BH; Arbogast PG; Cheetham TC; Quinn VP; Dublin S; Boudreau DM; Andrade SE; Pawloski PA; Raebel MA; Smith DH; Achacoso N; Uratsu C; Go AS; Sidney S; Nguyen-Huynh MN; Ray WA; Selby JV
    JAMA; 2011 Dec; 306(24):2673-83. PubMed ID: 22161946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.
    Dalsgaard S; Kvist AP; Leckman JF; Nielsen HS; Simonsen M
    J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):302-10. PubMed ID: 24956171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myocardial infarction induced by concurrent use of adderall and alcohol in an adolescent.
    Sharma J; de Castro C; Chatterjee P; Pinto R
    Pediatr Emerg Care; 2013 Jan; 29(1):84-8. PubMed ID: 23283274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of prescription stimulant for Attention Deficit Hyperactivity Disorder in Aboriginal children and adolescents: a linked data cohort study.
    Ghosh M; Holman CD; Preen DB
    BMC Pharmacol Toxicol; 2015 Dec; 16():35. PubMed ID: 26646429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.